Welcome to our dedicated page for Puma Biotechnology SEC filings (Ticker: PBYI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Puma Biotechnology, Inc. (PBYI) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. Puma is a Nasdaq-listed biopharmaceutical company focused on oncology, and its filings offer detailed insight into the commercialization of NERLYNX (neratinib) and the development of alisertib, as well as its broader financial and corporate position.
Through periodic and current reports, investors can review Puma’s quarterly and annual financial statements, including revenue from NERLYNX product sales, royalty revenue, operating costs and expenses, and research and development spending tied to programs such as the ALISCA-Lung1 and ALISCA-Breast1 Phase II trials. Forms 8-K furnish press releases on quarterly results and disclose items such as amendments to the company’s bylaws, giving context on governance and legal structure.
This page also surfaces any proxy statements and related governance documents, where available, that describe board composition, compensation policies, and equity incentive plans such as Puma’s 2017 Employment Inducement Incentive Award Plan. Form 4 and other insider transaction filings, when present, can help users monitor share transactions by directors and officers.
Stock Titan enhances Puma’s SEC filings with AI-powered summaries that highlight key points from lengthy 10-K and 10-Q reports, explain complex accounting or clinical development disclosures in plain language, and flag notable risk factor or pipeline updates. Real-time integration with EDGAR helps ensure that new PBYI filings, including material 8-Ks, appear promptly, allowing investors, analysts, and researchers to quickly understand how regulatory, financial, and clinical developments may affect Puma Biotechnology’s business and PBYI stock.
A company insider filed a Form 144 notice to sell 18,012 shares of common stock through Fidelity Brokerage Services on or about 01/07/2026, with an indicated aggregate market value of $105,892.55. The notice cites that there were 50,391,107 shares of this class outstanding, giving context for the size of the planned sale.
The shares to be sold come from restricted stock vesting on 01/02/2026, received from the issuer as compensation, with the same date shown as the payment date. In the past three months, the insider, identified as Alan Auerbach, previously sold 16,938 common shares on 01/06/2026 for $98,978.90.
Douglas Hunt filed a notice under Rule 144 to sell 5,014 shares of common stock through Fidelity Brokerage Services LLC on or about 01/07/2026 on the NASDAQ market. These 5,014 shares were acquired on 01/02/2026 via restricted stock vesting from the issuer as compensation. The filing notes that 50,391,107 shares of the issuer’s common stock were outstanding. During the prior three months, Hunt sold 3,973 common shares on 01/06/2026 for gross proceeds of 24,216.62.
A shareholder filed a Rule 144 notice to sell 6,405 shares of common stock of the issuer through Fidelity Brokerage Services LLC on 01/07/2026, with an aggregate market value of $37,655.00. The filing notes that there are 50,391,107 shares of this common stock outstanding and that the shares to be sold were acquired on 01/02/2026 via restricted stock vesting as compensation from the issuer. Over the prior three months, the same seller, Maximo Nougues, sold 4,540 common shares for gross proceeds of $26,529.94. The signer represents that they are not aware of undisclosed material adverse information about the issuer’s current or prospective operations.
An affiliate of the issuer has filed a notice of proposed sale under Rule 144 covering up to 3,973 shares of common stock. These shares are planned to be sold through Fidelity Brokerage Services LLC on the NASDAQ, with an approximate sale date of 01/06/2026 and an indicated aggregate market value of 23,216.62. The filing notes that 50,391,107 shares of this class were outstanding at the time referenced.
The 3,973 shares were acquired on 01/02/2026 directly from the issuer through restricted stock vesting as compensation. The section for securities sold during the past three months does not list any prior sales, and the signer represents that they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
Puma Biotechnology (PBYI) reported an insider transaction by a director. On 11/11/2025, the reporting person sold 20,000 shares of common stock at a weighted average price of $4.8614, with trades executed between $4.82 and $4.97. Following the sale, the insider directly owns 54,000 shares. The filing notes the seller will provide full trade‑level details upon request.
Puma Biotechnology (PBYI) reported Q3 2025 results. Total revenue was $54.5 million, with product revenue of $51.9 million and royalty revenue of $2.6 million. Net income was $8.8 million, or $0.17 per diluted share. Operating costs and expenses were $44.9 million, yielding income from operations of $9.6 million.
For the nine months ended September 30, 2025, revenue was $152.9 million and net income was $17.7 million. Operating cash flow totaled $27.4 million. Cash, cash equivalents and marketable securities were $94.4 million as of September 30, 2025. Long-term debt, net, was $0 at quarter-end, and the current portion of long-term debt was $33.7 million.
Stockholders’ equity rose to $115.3 million from $92.1 million at year-end. Shares outstanding were 50,391,107 as of November 3, 2025. The company continues to commercialize NERLYNX and to develop alisertib under its license from Takeda.
Puma Biotechnology (PBYI) reported that it issued a press release announcing financial results for the third quarter ended September 30, 2025. The press release is furnished as Exhibit 99.1 to this report.
The company states the information under Item 2.02 is being furnished, not filed under the Exchange Act and will not be incorporated by reference into other filings. Additional exhibits include Exhibit 104 (Cover Page Interactive Data File in inline XBRL).